TIDMETX

RNS Number : 7232G

e-Therapeutics plc

31 May 2017

e-Therapeutics plc

('e-Therapeutics' or the 'Company')

Results of Annual General Meeting

Oxford, UK, 31 May 2017 - e-Therapeutics plc (AIM: ETX) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 8 May 2017 were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.

-Ends-

Contacts:

 
 e-Therapeutics plc                   Tel: +44 (0) 1993 
  Ray Barlow, CEO                      883 125 
  Steve Medlicott, Finance Director    www.etherapeutics.co.uk 
 Numis Securities Limited             Tel: +44 (0) 207 260 
  Michael Meade / Freddie Barnfield    1000 
  (Nominated Adviser)                  www.numis.com 
  James Black (Corporate Broking) 
 Instinctif Partners                  Tel: +44 (0) 207 457 
  Melanie Toyne Sewell / Alex          2020 
  Shaw                                 Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUARORBRAVOAR

(END) Dow Jones Newswires

May 31, 2017 09:01 ET (13:01 GMT)

E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more E-therapeutics Charts.
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more E-therapeutics Charts.